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Abstract
Background: The human pregnane X receptor (hPXR) is an orphan nuclear receptor that induces
transcription of response elements present in steroid-inducible cytochrome P-450 gene
promoters. This activation requires the participation of retinoid X receptors (RXRs), needed
partners of hPXR to form heterodimers. We have investigated the expression of hPXR and RXRs
in normal, premalignant, and malignant breast tissues, in order to determine whether their
expression profile in localized infiltrative breast cancer is associated with an increased risk of
recurrent disease.
Methods: Breast samples from 99 patients including benign breast diseases, in situ and infiltrative
carcinomas were processed for immunohistochemistry and Western-blot analysis.
Results: Cancer cells from patients that developed recurrent disease showed a high cytoplasmic
location of both hPXR isoforms. Only the infiltrative carcinomas that relapsed before 48 months
showed nuclear location of hPXR isoform 2. This location was associated with the nuclear
immunoexpression of RXR-alpha.
Conclusion: Breast cancer cells can express both variants 1 and 2 of hPXR. Infiltrative carcinomas
that recurred showed a nuclear location of both hPXR and RXR-alpha; therefore, the
overexpression and the subcellular location changes of hPXR could be considered as a potential
new prognostic indicator.
Background
The human pregnane X receptor (hPXR, also known as
SXR) is a member of the NR1I2 subfamily [1]. This recep-
tor presents different isoforms that are differentially acti-
vated by a remarkably diverse collection of compounds
including both xenobiotics and natural steroids [2]. PXR
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files between species; thus, pregnenolone 16α-carboni-
trile is an efficacious activator of mouse and rat PXR, but
has much less activity on the human and rabbit receptors.
Conversely, rifampicin activates the human and rabbit
PXR but has no activity on the mouse or rat receptors [3].
PXR is a needed partner of RXRs [4] to form heterodimers
that induce transcription from ER6 [5] or IR6 [6] response
elements present in steroid-inducible cytochrome P450
(CYP) gene promoters [7]. Cytochrome P450 constitutes a
multigene family of hemoproteins responsible for the
metabolism of numerous xenobiotics, including thera-
peutic drugs, environmental chemicals and dietary con-
stituents, as well as endogenous compounds such as
steroids and bile acids [8]. Kliewer et al. [3] demonstrated
in mice that the strong activation of PXR evoked by the
pregnane compounds seemed to be mediated by CYP3A
induction; this effect also appeared in the homologous
counterparts of rat, rabbit, and humans [5,6,9,10].
CYP3A and hPXR are mainly expressed in the liver and the
intestine, and, to a lesser extent, in kidney and lung [11];
in addition CYP3A enzymes have been found in human
breast cancer tissue [12,13]. The tissue distribution and
the relative abundance of hPXR mRNA resemble CYP3A
expression very closely, suggesting that hPXR may be
important not only for induction but also for constitutive
expression of these enzymes [11]. Dotzlaw et al. [14] have
shown that the level of hPXR mRNA did not differ
between breast tumours and their adjacent matched nor-
mal breast tissues; however, among different breast
tumour types the expression of hPXR mRNA is diverse.
This suggests that hPXR is not significantly altered during
tumorigenesis but may display changes related to the can-
cer phenotype and the degree of differentiation [14].
However, Miki et al. [15] studied samples of atypical duc-
tal hyperplasia, ductal carcinoma in situ and invasive duc-
tal carcinoma of the human breast and they detected the
presence of neither hPXR mRNA nor protein in non-neo-
plastic breast tissues suggesting that hPXR is predomi-
nantly expressed in carcinoma cells.
Several studies have implicated different cytochrome
P450 proteins in the mechanisms of resistance to anties-
trogens (tamoxifen and toremifene), taxanes and other
anticancer compounds. Therefore, the study of the expres-
sion and regulatory pathways of P450 in cancer became
an active research field [16,17]; in contrast, studies con-
cerning hPXR are rarely found in the literature. Because
hPXR is related to the response to different antitumoural
treatments, we have investigated the distribution of this
orphan receptor and its needed partner RXRs in normal,
premalignant, and malignant breast tissues. Also, we ana-
lysed its relationship with the patient's clinicopathologi-
cal data to elucidate whether some differences in the
pattern of expression of these proteins occurred and
whether these differences could be valuable for prognostic
purposes.
Methods
Patients and histological samples
Breast samples from 99 patients randomly selected and
diagnosed by the Pathology Service of the Hospital Prínc-
ipe de Asturias and Hospital Virgen de la Victoria were
used with the consent of the patients and permission of
the Ethics Committees of Hospitals. Glandular lesions
were classified as follows: 12 cases of benign proliferative
diseases (BBDs) including ductal and lobular hyperplasia,
apocrine metaplasia, fibroadenoma and fibrocystic
changes; 10 carcinomas in situ (CIS); 77 infiltrative carci-
nomas, 54 ductal (IDC) and 23 lobular (ILC). Samples
were processed for immunohistochemistry (formalin fix-
ation and paraffin embedding) and for Western blot anal-
ysis (frozen with liquid nitrogen).
All infiltrative tumour samples were classified by the TNM
system; after surgery, the hormonal status of each tumour
was evaluated. These patients (from 35 to 91 years of age)
were diagnosed of localized breast cancer between 1998
and 2000 and they had a follow-up of 60 months. Dissec-
tion of axillary lymph nodes was carried out in all of cases.
None of them received radiotherapy, hormonal therapy
or chemotherapy before surgery. After immunohisto-
chemistry and Western blot analysis, we reviewed clinical
records and identified two patients' groups: Group 1)
Forty five patients did not relapse after a minimum period
of 24 mo. of follow-up (follow-up median 57 months,
range 24 to 61 mo.). Twenty four of the 45 cases showed
no evidence of ganglionar lesions at diagnosis (53.3%)
and 21 showed ganglionar metastasis (46.7%). Group 2)
Thirty two patients who relapsed with a median disease
free interval of 18.5 months (range 7 to 64 mo.). Three of
these 32 cases showed no ganglionar lesions at diagnosis
(9.4%) and 29 patients showed ganglionar metastasis
(90.6%). In the group 1, nineteen patients received adju-
vant therapy with tamoxifen, 20 were treated with chem-
otherapy and tamoxifen, 5 with chemotherapy only and 1
of them received radiotherapy. In the group 2, three
patients received adjuvance with tamoxifen, 19 tamoxifen
and chemotherapy, 4 received chemotherapy only and 5
adjuvant endocrine therapy without tamoxifen. 27
patients received a second-line of chemotherapy and 14
died between 2 and 32 months after the diagnosis of
metastasis.
Immunoblotting
For Western blot analysis, each sample was homogenised
in 0.5 M Tris-HCl buffer (pH 7.4) containing 1 mM EDTA,
12 mM 2-mercaptoethanol, 1 mM benzamidine, and 1Page 2 of 14
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addition of a cocktail of protease inhibitors (10 mM
iodoacetamide, 0.01 mg/ml of soybean trypsin inhibitor
and 1 μl/ml of leupeptin) and phosphatase inhibitors (10
mM sodium fluoride and 1 mM sodium orthovanadate)
in the presence of 0.5% Triton X-100. Homogenates were
centrifuged for 10 min at 15000 × g. After boiling for 2
min at 98°C, aliquots of 70 μg of protein were separated
in SDS-polyacrylamide (9% w/v) slab minigels. Separated
proteins were transferred for 4 h at 0.25 A to nitrocellulose
membranes (0.2 μm) and, thereafter, the nitrocellulose
sheets were blocked for 1 h with 5% blotto in 0.05 M Tris-
HCl and incubated overnight with the primary antibodies
diluted 1:200 (RXR-α and -γ), and 1:100 (RXR-β, hPXR1,
and hPXR1.2) in blocking solution 1:9 overnight at 37°C.
For RXRs, the blots were incubated with peroxidase-linked
secondary antibody (Chemicon) diluted 1:4000 for 1
hour at room temperature. For hPXR1 and hPXR1.2,
swine anti-goat and goat anti-rabbit biotinylated immu-
noglobulins (Dako, Barcelona, Spain) were used at
1:1000 dilution in blocking solution 1:9 for 1 h at room
temperature, and then the membranes were incubated
with streptavidin-peroxidase complex (Zymed, CA, USA).
Antibody/protein complexes were detected using ECL
(Amersham, Buckinghamshire, UK).
Extracts from breast cancer cell lines (MCF-7 and MDA-
MB-231) were used as positive controls for hPXR1.2 and
hPXR1 antibodies. Blots were stripped and re-probed with
an anti-human β-actin monoclonal antibody (Sigma) to
control for equal sample loading.
Immunohistochemistry
Sections of 5-μm-thickness were deparaffined, hydrated
and incubated for 20 min in 0.3% H2O2 to inhibit endog-
enous peroxidase activity, and for antigen retrieval, incu-
bated with 0.1 M citrate buffer (pH 6) for 10 min. at 96°C.
After rinsing in TBS, the slides were incubated with 3%
normal donkey serum (NDS) in TBS for 30 min to prevent
non-specific binding of the first antibody. Afterwards,
they were incubated overnight at 37°C with the RXR-α
and RXR-γ rabbit polyclonal antibodies and RXR-β mouse
monoclonal primary antibody (Santa Cruz Biotechnolo-
gies, CA, USA), diluted 1:20 in blocking solution 1:9; rab-
bit polyclonal hPXR (that reacts with the isoforms 1 and 2
of PXR) (Active Motif, Rixensart, Belgium) at 1:300 dilu-
tion, and goat polyclonal hPXR1 (isoform 1) diluted 1/20
(Santa Cruz). The sections were washed in TBS and incu-
bated with swine anti-goat (for hPXR1), swine anti-rabbit
(for hPXR1.2, RXR-α and RXR-γ), or rabbit anti-mouse
(for RXR-β) biotinylated immunoglobulins (Dako, Barce-
lona, Spain) all of them at 1:400 dilution during 1 h.
Thereafter, they were incubated with avidin-biotin-perox-
idase complex (Dako) and developed with 3, 3'-diami-
nobenzidine (DAB) using the glucose oxidase-DAB-nickel
intensification method. The sections were dehydrated,
cleared in xylene, and mounted in DePex (Probus,
Badalona, Spain).
To assess the specificity of immunoreactions, negative and
positive controls were used. As negative controls, sections
of breast samples processed identically were incubated
using the antibody preabsorbed with corresponding
blocking peptide, or omitting the primary antibody. As
positive controls, sections of human liver, intestine for
hPXR1.2 and hPXR1, and human skin for the three iso-
forms of RXR were processed with the same antibody.
The staining intensity of hPXR and RXRs receptors was
classified in two categories: 0, negative or staining was
observed in less than 10% of the cells; 1, staining was
detected in more than 10% of the cells. In contrast to
nuclear staining, the staining pattern of the extranuclear
expression for these proteins was observed in two types:
diffuse staining and spotted staining in the cytoplasm
according to the following criteria: score 0, no staining at
all; 1, a weak staining; 2, a moderate to strong staining was
observed in more than 10% of the tumour cells. The
assessment of the grade of staining was performed in a
blinded way always by the same experienced investigators
(IC, MIA) in high-power fields (×400) using standard
light microscopy.
Statistical analysis
To evaluate the differences between hPXR and RXRs
expression for each of the different pathology types
(BBDs, CIS, IDC and ILC), we performed overall compar-
isons using non-parametric ANOVA (Kruskal-Wallis test).
In infiltrative carcinomas, univariate analysis comparing
categorical variables (hPXR, RXR, ER and PR expression
and clinicopathological data) was performed using chi-
square tests. Given the low expected frequencies found in
the majority of the crosstabulations, we used Fisher exact
test to compute p-values. We test for the presence of a lin-
ear trend when there were more than two categories of
staining using Mantel-Haenszel chi-square statistic. Time
to post-operative recurrence was analyzed using Kaplan-
Meier estimations of disease free survival curves. Survival
curves were compared with log-rank test. We adopt a 5%
significance level. All analyses were performed with SPSS
version 13.0 for Windows.
Results
Western blot analysis
Results from Western blot analysis are shown in Figure 1.
In breast cancer cell lines, hPXR1.2 antibody showed two
distinctive immunoreactive bands at 40 and 70 kDa; in
MDA-MB-231 cells an additional band at 90 kDa and
other fainter band at ~28 kDa were observed. In CIS, threePage 3 of 14
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carcinomas showed a strong band at 40 kDa, and addi-
tional protein bands at 50 and 70 kDa. When the same
samples were incubated with the antibody that exclusively
recognizes the hPXR1 isoform, multiple bands were
observed in MDA-MB-231 cells, at approximately 28, 40,
70, 120 and 250 kDa (Fig. 1B). In MCF-7 cells only the 70,
120 and 250 KDa were detected. Carcinomas in situ sam-
ples showed the same three bands detected with hPXR1.2
antibody at 50, 100 and 160 kDa. In infiltrative carcino-
mas, hPXR1 antibody detected immunoreactive protein
bands at approximately 50, 70, 120 and 250 kDa. No
immunoreaction to hPXR1.2 or to hPXR1 was detected in
samples from benign breast diseases.
A. Western blot analysis for hPXR1.2 and hPXR1 antibodiesFigur  1
A. Western blot analysis for hPXR1.2 and hPXR1 antibodies. With hPXR1.2 antibody, in MCF-7 cells were detected 
mainly two bands at 40 and 70 kDa; however, in MDA-MB-231 can be also observed additional bands at 28 and 90 kDa. In this 
last cell line, with hPXR1 antibody multiple bands at 28, 37, 40, 70, 120 and 250 kDa; however, in MCF-7 were only detected 
bands at 70, 120 and 250 kDa. In benign breast diseases no bands were observed either with hPXR1.2 or with hPXR1 antibody. 
In carcinomas in situ, bands at 50, 100 and 160 kDa were observed with both antibodies. In infiltrative carcinomas, those sam-
ples incubated with hPXR1.2 presented multiple bands at approximately 40, 50 and 70 kDa.; while in samples incubated with 
hPXR1 antibody, five immunoreactive bands at 40, 50, 70, 120 and 250 kDa were observed. B. Western blot analysis for 
RXRs antibodies. For RXR-α, RXR-β and RXR-γ, only a single band at 60 kDa of molecular weight was found in all patholo-
gies studied. For all figures: Lane 1: MCF-7 cells. Lane 2: MDA-MB-231 cells. Lane 3: benign breast diseases. Lane 4: Ductal car-
cinoma in situ. Lanes 5 and 6: Lobular carcinoma in situ. Lane 7: Infiltrative ductal carcinoma. Lane 8: Infiltrative lobular 
carcinoma. Each blot is representative of its respective group. After stripping, immunoreactivity with an anti-actin antibody was 
used as loading control (actin, bottom panels).Page 4 of 14
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bodies showed a single band with a molecular weight of
60 kDa.
Immunohistochemical study of control sections
The immunohistochemical study showed no reaction in
the negative controls obtained when they were incubated
with antibody pre-absorbed with blocking peptide (Fig.
2A). Positive controls for hPXRs antibodies showed an
intense immunoreaction in the cytoplasm of hepatocytes
(Figure 2B). Immunostaining of human skin sections
were always positive to RXRs antibodies (Figure 2C).
Immunohistochemical detection of hPXR
hPXR1.2 was detected in the cytoplasm in the most of
samples (Table 1). In normal breast ducts and acini, only
some myoepithelial and endothelial cells were immuno-
reactive. In BBDs, a cytoplasmic immunoreaction to
hPXR1.2 in the epithelial cells was also detected (Fig. 3A).
Carcinomatous lesions showed some variations in
hPXR1.2 expression; thus, 90% of CIS showed cytoplas-
mic reaction (Fig. 3B); while in IDC, the 100% of samples
presented cytoplasmic reaction, and the 45.8% of samples
showed nuclear immunolabelling (Fig. 3C). Infiltrative
lobular carcinomas showed higher nuclear immunoreac-
tion (80%) (Fig. 3D).
hPXR1 isoform showed a similar expression pattern to
hPXR1.2 in benign lesions and CIS (Figs. 3E and 3F).
However, infiltrative carcinomas only showed cytoplas-
mic immunoreactivity (Figs. 3G and 3H).
A. Negative control section of infiltrative ductal carcinoma was obtained when it was incubated with antibody pre-absorbed with blocking peptide (×250)Figure 2
A. Negative control section of infiltrative ductal carcinoma was obtained when it was incubated with antibody pre-absorbed 
with blocking peptide (×250).B. Control section from human liver with an intense reaction to hPXR1.2 antibody in the cyto-
plasm of hepatocytes (×250). C. Control section of human skin. The nuclei of keratinocytes were intensely labelled for RXRa 
(×250).
Table 1: Immunohistochemical expression of Retinoid X receptors and hPXR isoforms in human breast lesions.
BBDs (n = 12) CIS (n = 10) IDC (n = 54) ILC (n = 23) p-value1
N C N C N C N C N C
hPXR1.2 0 6 (50%) 0 9 (90%) 15 (27.8%) 54 (100%) 7 (30.4%) 23 (100%) 0.048 <0.001
hPXR1 0 4 (33.4%) 0 8 (80%) 0 54 (100%) 0 23 (100%) 1.000 <0.001
RXR-α 0 1 (8.4%) 0 2 (20%) 23 (42.6%) 25 (46.3%) 11 (47.8%) 8 (34.8%) 0.002 0.037
RXR-β 0 0 0 3 (30%) 8 (14.8%) 30 (55.6%) 2 (8.7%) 12 (52.1%) 0.301 0.003
RXR-γ 0 2 (16.7%) 0 4 (40%) 8 (14.8%) 35 (64.8%) 5 (21.7%) 10 (43.5%) 0.161 0.002
Numbers represent the frequencies and percentages of cases with positive reaction. BBDs: benign breast diseases. CIS: carcinoma in situ. IDC: 
infiltrative ductal carcinoma. ILC: infiltrative lobular carcinoma. n: number of cases. N: nucleus. C: cytoplasm. 1p-values obtained by one-way 
Kruskal-Wallis test to compare overall between pathological groups differences in the degree of staining.Page 5 of 14
(page number not for citation purposes)
BMC Cancer 2008, 8:174 http://www.biomedcentral.com/1471-2407/8/174
Page 6 of 14
(page number not for citation purposes)
Immunohistochemical detection of hPXR and RXR receptorsFigure 3
Immunohistochemical detection of hPXR and RXR receptors. Immunoreaction to hPXR1.2 (A, B, C and D). In 
ductal hyperplasia (A) (×250) and ductal carcinoma in situ (B) (×250), the reaction was observed in the cytoplasm. In infiltrative 
ductal carcinoma (C) (×250) and infiltrative lobular carcinoma (D) (×500), the hPXR1.2 immunoexpression was also observed 
in the nucleus of neoplastic cells. Immunoreaction to hPXR1 (E, F, G and H). Lobular hyperplasia (E) (×200) showing no 
immunoreaction to hPXR1 antibody. Micrograph of lobular carcinoma in situ (F) (×200), infiltrative ductal carcinoma (G) 
(×200) and infiltrative lobular carcinoma (H) (×200) with cytoplasmic immunolocation of hPXR1 isoform. Immunoreaction 
to RXR-α (I, J, K and L). Cytoplasmic immunolabelling of RXR-α in samples of ductal hyperplasia (I) (×200) and ductal carci-
noma in situ (J) (×300). Neoplastic cells from infiltrative ductal carcinoma (K) (×300) and infiltrative lobular carcinoma (L) 
(×500) presenting a nuclear immunoexpression to RXR-α.
BMC Cancer 2008, 8:174 http://www.biomedcentral.com/1471-2407/8/174The most important difference between the patient groups
was that patients who evolved to recurrent disease showed
cells with nuclear staining to PXR1.2 antibody, but these
nuclei were consistently immunonegative to PXR.1.
Immunohistochemical expression of retinoid receptors
Both benign samples and CIS showed only cytoplasmic
immunoreaction to RXR-α (Figs. 3I and 3J). However, in
both ductal and lobular infiltrative carcinomas this recep-
tor was also observed in the nucleus of neoplastic cells
(Figs. 3K and 3L).
The percentage of positive cases for RXR-β was similar to
that of RXR-α in BBDs and CIS, and lower in infiltrative
carcinomas; in IDC, only one case of nuclear immunore-
action was observed.
The immunoexpression observed for RXR-γ was similar to
that of RXR-α, although the percentage of samples with
cytoplasmic immunoreaction was always higher and
lower that of nuclear expression.
Statistical analysis
The Fisher's exact tests realized between the RXR and
hPXR isoforms (Table 2) showed a positive association
between the expression of hPXR isoforms and nuclear and
cytoplasmic RXR-α expression. Also, a positive association
between the expression of both hPXR isoforms and cyto-
plasmic expression of both RXR-β and RXR-γ was encoun-
tered.
The associations between the hPXR isoforms expression
and the clinicopathological data of patients are reflected
in Table 3. Patient's age was homogeneous and independ-
ent on hPXR results. hPXR expression was not associated
with tumour type. The nuclear hPXR1.2 expression was
significantly more frequent in patients with positive nodal
status. hPXR expression was inversely correlated with ER
expression while that of PR was correlated with the
nuclear and cytoplasmic expression of hPXR1.2 and the
hPXR1 cytoplasmic expression. hPXR expression was
inversely correlated with recurrence and disease-free inter-
val (Fig. 4).
The associations between the RXRs expression and the
clinicopathological data are reflected in Tables 4 and 5.
Table 2: Fisher's exact test between the expression of the different isoforms of hPXR and that the retinoid receptors in infiltrative 
carcinomas.
hPXR1.2 C hPXR1.2 N hPXR1 C
Total Weak High p-value Negative Positive p-value Weak High p-value
RXR-α C Negative 45 17 28 0.035 24 21 <0.001 19 26 0.007
Weak 6 5 1 6 0 5 1
High 26 16 10 25 1 20 6
Total 77 38 39 55 22 44 33
RXR-α N Negative 43 30 13 <0.001 42 1 <0.001 34 9 <0.001
Positive 34 8 26 13 21 10 24
Total 77 38 39 55 22 44 33
RXR-β C Negative 35 18 17 0.021 22 13 0.045 18 17 0.329
Weak 18 13 5 17 1 13 5
High 24 7 17 16 8 13 11
Total 77 38 39 55 22 44 33
RXR-β N Negative 67 32 35 0.470 48 19 0.915 38 29 0.845
Positive 10 6 4 7 3 6 4
Total 77 38 39 55 22 44 33
RXR-γ C Negative 32 21 11 0.001 28 4 0.001 24 8 <0.001
Weak 12 9 3 11 1 10 2
High 33 8 25 16 17 10 23
Total 77 38 39 55 22 44 33
RXR-γ N Negative 64 34 30 0.142 46 18 0.847 37 27 0.792
Positive 13 4 9 9 4 7 6
Total 77 38 39 55 22 44 33
C: Cytoplasmic immunoreaction. N: nuclear immunoreaction.Page 7 of 14
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of both RXR-β and RXR-γ. The cytoplasmic expression of
RXR-γ was inversely correlated with ER and PR expression
and RXR-α nuclear expression was correlated with that of
PR. Relapse and survival were correlated with cytoplasmic
expression of RXR-β and RXR-γ and with nuclear expres-
sion of RXR-α (Fig. 5).
Discussion
hPXR has been shown to activate transcription of reporter
genes through a response element conserved in the pro-
moter of the CYP3A genes [3,5], suggesting that hPXR
might be a transcriptional regulator of CYP3A expression
[5]. Because these CYP3A enzymes have also been found
in human breast cancer tissues [13,18], hPXR/CYP3A-reg-
ulated pathways might be involved in therapy response of
breast cancer. Thus, the first step to evaluate the functions
of hPXR/CYP3A in breast cancer it would be to determi-
nate the expression pattern of the hPXR proteins. This
study provides evidence that both hPXR isoforms are
expressed in human breast cancer but not in normal
glands, although a previous report showed that theirs
transcripts are expressed in both normal and neoplastic
human breast tissue [14]. Our findings suggest that trans-
lation of mRNA might only occurs in breast cancer; simi-
lar results have been reported by Miki et al. [15] who
detected the presence of hPXR mRNA and protein in
breast carcinomatous tissues but not in nonneoplastic
and stromal cells.
The presence of different hPXR isoforms in breast lesions
has been observed by Western blot analysis. By using
MCF-7 and MDA-MB-237 cells to control antibodies
immunoreactivity, we observed that the latter presented
multiple distinctive bands and that the bands at 28 and 90
kDa probably belong to the hPXR.2 isoform. Samples
from CIS showed identical immunoreactive bands with
the two antibodies we used. Furthermore, infiltrative car-
cinomas showed a similar pattern to that encountered in
MDA-MB-231 cells. These results agree with previous
findings that suggest that hPXR is expressed as multiple
forms, due to alternative as well as defective gene splicing
[19]; therefore, in the same tissue, interindividual differ-
ences in hPXR transcript and protein profiles may exist. In
addition, a different expression of three PXR isoforms
have been detected in human liver and hepatoma cells,
stomach, adrenal gland, bone marrow and brain [2,20].
A previous report showed that mRNA of hPXR variants 1
and 2 is expressed in several cell lines, such as MCF-7 or
Table 3: Fisher's exact test between hPXR expression and different clinicopathological data of the patients presenting infiltrative 
carcinomas.
hPXR1.2 C hPXR1.2 N hPXR1 C
Total Weak High p-value Negative Positive p-value Weak High p-value
Tumor Type Ductal 54 26 28 0.613 39 15 0.002 33 21 0.374
Lobular 22 12 10 16 6 11 11
Age <50 19 13 6 0.055 13 6 0.738 12 7 0.542
>50 58 25 33 42 16 32 26
Tumor size 1 31 20 11 0.083 27 4 0.077 23 8 0.088
2 33 15 18 21 12 16 17
3 5 1 4 3 2 2 3
4 8 2 6 4 4 3 5
Nodal status - 35 20 15 0.212 30 5 0.011 21 14 0.644
+ 42 18 24 25 17 23 19
ER 0 17 7 10 0.257 9 8 0.001 10 7 0.161
1 6 1 5 1 5 1 5
2 12 6 6 9 3 6 6
3 42 24 18 36 6 27 15
PR 0 21 10 11 0.031 14 7 0.000 12 9 0.004
1 7 0 7 0 7 0 7
2 13 6 7 10 3 6 7
3 36 22 14 31 5 26 10
Tumor size (TNM): T = 1, 2, 3, 4. ER and PR: 0 = Negative, 1 = Weak immunoreaction, 2/3 = High immunoreaction. C: Cytoplasmic 
immunoreaction. N: nuclear immunoreaction.Page 8 of 14
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Kaplan-Meier disease-free survival curves for 77 patients with infiltrative carcinomas according to the hPXR expressionFigure 4
Kaplan-Meier disease-free survival curves for 77 patients with infiltrative carcinomas according to the hPXR 
expression. Marks represent censored data. Statistical significance was determined by the Log Rank test.
Table 4: Fisher's exact test between RXRs cytoplasmic expression and different clinicopathological data of the patients presenting 
infiltrative carcinomas.
RXR-α C RXR-β C RXR-γ C
Negative Weak High p-value Negative Weak High p-value Negative Weak High p-value
Tumor 
Type
Ductal 30 3 21 0.264 24 12 18 0.838 19 10 25 0.151
Lobular 14 3 5 10 6 6 13 2 7
Age <50 12 3 4 0.185 10 4 5 0.765 5 3 11 0.254
>50 33 3 22 25 14 19 27 9 22
Tumor size 1 15 4 12 0.697 12 11 8 0.292 15 7 9 0.392
2 22 2 9 17 4 12 12 5 16
3 3 0 2 1 2 2 2 0 3
4 5 0 3 5 1 2 3 0 5
Nodal 
status
- 22 3 10 0.678 17 12 6 0.024 18 9 8 0.003
+ 23 3 16 18 6 18 14 3 25
ER 0 10 0 7 0.274 6 2 9 0.060 2 3 12 0.000
1 6 0 0 3 0 3 1 0 5
2 6 2 4 4 6 2 2 4 6
3 23 4 15 22 10 10 27 5 10
PR 0 13 1 7 0.296 11 5 5 0.480 9 2 10 0.009
1 7 0 0 3 0 4 0 0 7
2 8 1 4 5 5 3 4 5 4
3 17 4 15 16 8 12 19 5 12
Tumor size (TNM): T = 1, 2, 3, 4. ER and PR: 0 = Negative, 1 = Weak immunoreaction, 2/3 = High immunoreaction. C: Cytoplasmic 
immunoreaction.
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related to the ER status. The ER status is used as a thera-
peutic indicator and is also a prognostic marker in human
breast cancer [21]. We have observed that the neoplastic
cells that express nuclear hPXR1.2 and no ER immunore-
activity were strongly correlated; this inverse correlation
between both receptors suggests that pathways by hPXR-
mediated might be functional in breast tumours with
potential poor response to the endocrine adjuvance. This
correlation between ER and hPXR was also found by Mas-
uyama et al. [23] in human endometrium; these authors
only detected hPXR expression in endometrial cancer tis-
sues but not in normal endometrium and, similarly they
encountered a significant inverse correlation between the
expression of PXR and ER. Altogether, these results suggest
that hPXR might play some role in the metabolism of ster-
oid hormones in tumoral cells, and that may be involved
in the growth and development of cancer tissue that
express low ER-alpha.
We have also analysed ER and hPXR cytoplasmic expres-
sion observing the same inverse correlation between both
receptors as that encountered for the nuclear immunolo-
cation. This is in agreement to the observation by Dotzlaw
et al. [14] who reported that MCF-7 cells (ER+/PR+), with
a low metastatic potential, express hPXR1 mRNA but not
hPXR.2 mRNA. However, MDA-MB-231 cells (ER-/PR-)
with a high metastatic potential, showed the highest levels
of both hPXR1 and 2 mRNA variants.
In breast cancer, the hPXR isoform 2 seems to be a func-
tional protein since it was detected in the cell nuclei. It has
been reported, in mouse liver, that PXR is retained in the
cytoplasm in a complex formed by hsp90 and the co-
chaperone CCRP, and in presence of ligand, PXR is accu-
mulated in the nucleus [24]. We have observed an
increase of the hPXR expression in both nucleus and cyto-
plasm related to breast cancer progression; the biological
significance of this rise correlated to neoplastic transfor-
mation is unknown; clearly, more studies are needed to
elucidate this accumulation. Although the percentage of
samples with nuclear immunostaining was lower than the
cytoplasmic staining, the specimens with nuclear reaction
corresponded to all those cases that presented resistance
to conventional treatments and that metastasized later.
Therefore, an important correlation between cancer recur-
rence and nuclear immunostaining of hPXR1.2 was
observed.
Table 5: Fisher's exact test between RXRs nuclear expression and different clinicopathological data of the patients presenting 
infiltrative carcinomas.
RXR-α N RXR-β N RXR-γ N
Negative Positive p-value Negative Positive p-value Negative Positive p-value
Tumor Type Ductal 31 23 0.819 46 8 0.503 46 8 0.406
Lobular 12 10 20 2 17 5
Age <50 9 10 0.391 17 2 0.713 17 2 0.394
>50 34 24 50 8 47 11
Tumor size 1 21 10 0.304 27 4 0.829 26 5 0.123
2 17 16 28 5 30 3
3 2 3 5 0 3 2
4 3 5 7 1 5 3
Nodal status - 19 16 0.802 28 7 0.095 28 7 0.505
+ 24 18 39 3 36 6
ER 0 8 9 0.093 15 2 0.254 16 1 0.116
1 1 5 6 0 6 0
2 6 6 12 0 11 1
3 28 14 34 8 31 11
PR 0 13 8 0.010 18 3 0.608 17 4 0.641
1 0 7 7 0 7 0
2 6 7 12 1 11 2
3 24 12 30 6 29 7
Tumor size (TNM): T = 1, 2, 3, 4. ER and PR: 0 = Negative, 1 = Weak immunoreaction, 2/3 = High immunoreaction. N: nuclear 
immunoreaction.Page 10 of 14
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superfamily where all members are ligand-activated tran-
scription factors, among them RXR is unique to this group
for its ability to interact with other receptors and form het-
erodimers complexes [25,26]. For Lawrence et al. [27], the
overexpression of RXRs isoforms in ductal carcinoma in
situ, especially RXR-α, indicate an association with an
increased risk for the development of invasive breast can-
cer. Ariga et al. [28] detected a widely distributed expres-
sion of the three RXR isoforms in ductal carcinomas in
situ; however, other authors detected RXR-γ expression
neither in breast cancer cell lines [28] nor in invasive duc-
tal breast carcinoma [29]. None of these authors have
reported cytoplasmic expression for these receptors that
we have detected, the differences in immunolocation
might be related to either the absence of ligand or the anti-
Kaplan-Meier disease-free survival curves for 77 patients with infiltrative carcinomas according to the RXR expressionFigure 5
Kaplan-Meier disease-free survival curves for 77 patients with infiltrative carcinomas according to the RXR 
expression. Marks represent censored data. Statistical significance was determined by the Log Rank test.Page 11 of 14
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nuclear receptors (steroids receptors) are found as an inac-
tive cytoplasmic form in a complex with heat shock pro-
teins [30]. It is also possible that inactive retinoic acid
nuclear receptors were forming a complex with heat shock
proteins in the cytoplasm. With breast cancer progression,
we have detected an increase in the percentage of samples
positives for RXRs isoform; since RXR are needed partners
of different nuclear receptors and there is an alternative
pathway of activation for RXR as a homodimer by binding
to a unique response element [31], this increase could be
related to the several modifications that occur in the
malignant progression.
The function of each RXR subtype in the mammary gland
has yet to be defined although some studies have demon-
strated an interaction between estrogen action and RXR
specifically with RXR-α [29,32]. The correlation between
the expression of RXR-α and hPXR observed in this study
supports the idea of dimerization of both receptors. Previ-
ous reports showed that different xeno-sensor target genes
have different sensitivity to different xenobiotics and that
RXR-α has an effect in gene regulation whereas RXR-β and
RXR-γ do not [4]. Cai et al. [22] demonstrated similar data
in mice that carried a RXR-α mutation; in hepatocytes, the
level of RXR-α controls the basal transcription of CYP450
genes.
One of the most important drugs developed for breast
cancer treatment is tamoxifen, used for systemic treatment
for nearly three decades [33,34]. Although tamoxifen has
been shown to be effective in the most tumours, some of
them are unresponsive, by acquiring eventually resistance
to this drug or well their growth becomes stimulated by it.
There are many possible mechanisms to explain this
resistance including the down-regulation, mutation, or
loss of estrogen receptors, impaired co-activator signal-
ling, and altered tamoxifen pharmacology [35].
The metabolism of tamoxifen is mainly regulated by the
P450 family of cytochromes, which catalyze its conver-
sion to both active and inactive products. In human liver
CYP3A4 regulates the conversion of tamoxifen into its
main active metabolite, 4-OH-tamoxifen [36]. Also,
hepatic CYP3A4 can be up-regulated by hPXR throughout
a mechanism involving the tamoxifen/4-OH-tamoxifen
[37].
In normal human breast and breast cancer several
CYP450 enzymes has been described [16,18,38], as well
as the expression of the CYP3A mRNA splicing forms [18].
Also, these studies showed a possible relationship among
the different enzyme subclasses and the development,
progression or response to antineoplastic agents [39].
Therefore, the machinery for possible in situ bioactivation
of xenobiotics and modification of therapeutic drugs is
present in human breast tissue. There are few available
data about the relationship between tamoxifen and hPXR/
CYP450, Sane et al. [40] have reported that the CYP3A4
induction by tamoxifen and 4-OH-tamoxifen is primarily
mediated by hPXR but the overall stoichiometry of other
nuclear receptors such as GR and ER-α also contribute to
the extent of the inductive effect. Huang et al. [18] consid-
ered that intratumoral hPXR levels might be useful as a
predictor of response to adjuvant therapy in breast cancer
patients. Synold et al. [41] have proposed that a classifica-
tion of tumours as hPXR-positive or hPXR-negative might
help predict whether the tumour is likely to develop
chemotherapy-induced drug resistance. Our results agree
with those observations since we observed that the higher
levels of hPXR variants 1 and 2 are related to shorter dis-
ease-free intervals and either local recurrences or progres-
sive disease.
Conclusion
In infiltrative carcinomas, the isoform responsible for
hPXR activity is the isoform 2. This isoform binds espe-
cially to RXR-α to form heterodimers which that activate
transcriptional pathways in breast neoplastic cells. Since
nuclear immunolocation occurs in samples from patients
who presented recurrence, we suggest that the overexpres-
sion and the subcellular location changes of hPXR could
be considered as a potential new prognostic indicator.
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